title: The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.
authors.forename: C
authors.initials: C
authors.lastname: Kellner
authors.forename: E A
authors.initials: EA
authors.lastname: Zhukovsky
authors.forename: A
authors.initials: A
authors.lastname: Pötzke
authors.forename: M
authors.initials: M
authors.lastname: Brüggemann
authors.forename: A
authors.initials: A
authors.lastname: Schrauder
authors.forename: M
authors.initials: M
authors.lastname: Schrappe
authors.forename: M
authors.initials: M
authors.lastname: Kneba
authors.forename: R
authors.initials: R
authors.lastname: Repp
authors.forename: A
authors.initials: A
authors.lastname: Humpe
authors.forename: M
authors.initials: M
authors.lastname: Gramatzki
authors.forename: M
authors.initials: M
authors.lastname: Peipp
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology*; D018941:Antigens, CD19 / Q000276:immunology*; D005260:Female; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000628:therapy*; D061251:Primary Cell Culture
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018941:Antigens, CD19; D007141:Immunoglobulin Fc Fragments; C000613469:tafasitamab